Horizon Pharma Ord (HZNP) 18.89 $HZNP Market Updates on

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Horizon Pharma Ord (HZNP) 18.89 $HZNP

Market Updates on Drugs - Generic Equities -- Mylan, Horizon Pharma, Allergan, and Diplomat Pharmacy
PR Newswire - Fri Jul 15, 6:30AM CDT
On Thursday, July 14, 2016, the NASDAQ Composite ended the trading session at 5,034.06, up 0.57%; the Dow Jones Industrial Average edged 0.73% higher, to finish at 18,506.41; and the S&P 500 closed at 2,163.75, up 0.53%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Allergan PLC (NYSE: AGN), and Diplomat Pharmacy Inc. (NYSE: DPLO). Learn more about these stocks by accessing their free notes at:
AGN: 254.86 (+1.91), DPLO: 35.72 (-0.21), HZNP: 18.89 (-0.40), MYL: 46.74 (-0.05)

Nuvo Pharmaceuticals(TM) Inc. Announces Pennsaid 2% Phase 3 Trial to Support Regulatory Approvals in the E.U., Canada and Australia
CNW Group - Wed Jul 13, 6:30AM CDT
Nuvo Pharmaceuticals Inc. (TSX:NRI) (Nuvo or the Company) today announced it will conduct a new placebo-controlled, multi-centre Phase 3 trial (Trial) in Germany to study Pennsaid 2% for the treatment of acute ankle sprains. Topline results of the Trial are expected to be available in late Q2 or early Q3 2017. The Trial is subject to approval by German regulatory authorities and the ethical review committee. Pennsaid 2% is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of the pain of osteoarthritis of the knee(s). The Trial will be conducted to support regulatory applications for marketing approval of Pennsaid 2% for the treatment of acute pain in the E.U., Canada and Australia. The Company believes that most other jurisdictions will base their marketing approval on existing data, including the current U.S. FDA approval of Pennsaid 2% and will not require additional clinical efficacy data. The Trial will cost approximately CDN$1.5 million spread over the second half of 2016 and the first half of 2017. The Company believes that potential revenue to be generated by the Trial far exceeds its modest cost.
NRI.TO: 6.93 (-0.07), HZNP: 18.89 (-0.40)

Looking for Bargain Stocks? Pick These 5 with Low P/B Ratio
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 9:57AM CDT
The P/B ratio is used to calculate how much an investor needs to pay for each dollar of book value of a stock.
MNK: 67.37 (+0.03), PMC: 26.42 (-0.14), KEP: 27.37 (+0.18), HZNP: 18.89 (-0.40), SEM: 11.27 (-0.23)

Drugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon Pharma, and Celator Pharma
PR Newswire - Fri Jun 17, 7:00AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Allergan PLC (NYSE: AGN), Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), and Celator Pharmaceuticals Inc. (NASDAQ: CPXX). Learn more about these stocks by accessing their free trade alerts at:
CPXX: 30.24 (unch), AGN: 254.86 (+1.91), HZNP: 18.89 (-0.40), MYL: 46.74 (-0.05)

Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting
PR Newswire - Tue Jun 07, 2:42PM CDT
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2016 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated May 4, 2016 were elected as directors of the Company.
NRI.TO: 6.93 (-0.07), HZNP: 18.89 (-0.40)

Nuvo Pharmaceuticals(TM) Announces Director Election Results of its Annual General Meeting
CNW Group - Tue Jun 07, 2:42PM CDT
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2016 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated May 4, 2016 were elected as directors of the Company.
NRI.TO: 6.93 (-0.07), HZNP: 18.89 (-0.40)

Horizon Pharma plc to Participate in Jefferies 2016 Healthcare Conference
Marketwired - Thu Jun 02, 6:00AM CDT
DUBLIN, IRELAND--(Marketwired - Jun 2, 2016) - Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that the company will present at the Jefferies 2016 Healthcare Conference at 2 p.m. EDT on June 9, 2016 in New York City, NY.
HZNP: 18.89 (-0.40)

Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (naproxen/esomeprazole) Delayed Release Tablets
Marketwire Canada - Wed Jun 01, 6:00AM CDT
Will Represent the Fifteenth U.S. Patent Listed in the Orange Book for VIMOVO
HZNP: 18.89 (-0.40), ARZ.TO: 4.56 (-0.07), ARLZ: 3.89 (+0.39)

Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
Arpita Dutt - Zacks Investment Research - Wed May 25, 2:02PM CDT
Deals and acquisitions were in focus this week in the biotech sector while AbbVie's (ABBV) recently in-licensed candidate fared well in a mid-stage study.
VRTX: 98.20 (+1.20), HZNP: 18.89 (-0.40), ICPT: 169.72 (-3.31), ABBV: 66.94 (+0.71), ACOR: 25.13 (-0.15), BIOD: 0.41 (-0.03), XNPT: 7.07 (+0.05)

Horizon (HZNP) to Buy Global Rights to Actimmune, Stock Down
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:10AM CDT
Horizon Pharma (HZNP) will acquire global rights to Actimmune from Boehringer Ingelheim. The deal is expected to close by year end.
ANIP: 61.06 (+0.46), HZNP: 18.89 (-0.40), RTRX: 18.17 (+0.24), BMY: 76.19 (+1.38)

Horizon Pharma plc to Acquire Worldwide Rights to Interferon Gamma-1b From Boehringer Ingelheim International GmbH
Marketwire Canada - Thu May 19, 6:00AM CDT
Also Licenses Rights to Patents and Pending Applications Covering Methods for Treating Friedreich's Ataxia With Interferon Gamma-1b; Company Currently Owns the Rights to Interferon Gamma-1b Under the Trade Name ACTIMMUNE(R) in the United States, Canada and Japan
HZNP: 18.89 (-0.40)

Horizon Pharma plc to Participate in UBS Global Healthcare Conference
Marketwire Canada - Wed May 18, 4:45PM CDT
DUBLIN, IRELAND--(Marketwired - May 18, 2016) - Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that Timothy P. Walbert, chairman, president and chief executive officer, will present at the UBS Global Healthcare Conference at 11 a.m. EDT on May 25, 2016 in New York City, NY.
HZNP: 18.89 (-0.40)

Horizon Pharma plc Announces That Marilyn Vetter Honored as a 2016 Healthcare Businesswomen's Association Luminary
Marketwired - Thu May 12, 7:00AM CDT
DUBLIN, IRELAND--(Marketwired - May 12, 2016) - Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that Marilyn Vetter, vice president, government and public affairs, has been named a 2016 Healthcare Businesswomen's Association (HBA) Luminary. Marilyn will be honored today at the 27th annual Woman of the Year event in New York.
HZNP: 18.89 (-0.40)

Horizon Pharma plc Announces Settlement of PENNSAID(R) (diclofenac sodium topical solution) 2% w/w Patent Litigation With Teligent, Inc.
Marketwire Canada - Thu May 12, 6:00AM CDT
DUBLIN, IRELAND--(Marketwired - May 12, 2016) - Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that its affiliates have entered into a settlement and license agreement with Teligent, Inc. to resolve pending patent litigation involving PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID® 2%).
HZNP: 18.89 (-0.40), TLGT: 8.29 (+0.17)

Nuvo Pharmaceuticals™ Announces 2016 First Quarter Results
PR Newswire - Wed May 11, 4:00PM CDT
Revenue and gross margin increase - - Nuvo to Host Conference Call/Audio Webcast May 12th at 8:30 a.m. ET -
NRI.TO: 6.93 (-0.07), HZNP: 18.89 (-0.40)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Century's Florence Model Openings Put Arizona in Focus

Updated Category News Views 18

Six furnished houses in Florence may sound like a modest ribbon-cutting, but homebuilding is a business of small field signals before the quarterly numbers ever show up. Century Communities is scheduled to host a November grand opening for six model homes spanning two new communities in Florence, Arizona. For investors tracking NYSE:CCS, that is not a thesis by itself. It...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 15

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 88

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
The Estate Bets Over $1 Billion on Luxury Longevity

Updated Category News Views 0

A billion-dollar wellness promise just wandered into the condominium market. The Estate by sbe says its first three branded residential developments carry combined real estate value above $1 billion and encompass more than 500 units. That is not pocket change, and it is certainly not a routine hotel-brand licensing exercise dressed up with scented candles and a cold...

Continue Reading
Hitachi's Quiet Fusion Bet Is Really About Data Control

Updated Category News Views 16

Weeks of engineering work can vanish because one storage system hiccups, which is a rotten way to learn that data infrastructure belongs in the mission-critical column. Esteyco’s new environment, built with Hitachi Vantara and implemented by Quadrics Sistemas, is not a fusion breakthrough. It is the less glamorous machinery that keeps serious fusion research from...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 0

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 87

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
Ivanti's AI Push Rests on Data, Control and Results

Updated Category News Views 107

Enterprise AI has a nasty habit of sounding brilliant right up until it meets a messy fleet of laptops, phones, patches and permissions. Ivanti’s latest product push is aimed squarely at that unglamorous collision point: giving AI systems governed access to the operational data inside Ivanti Neurons, then keeping humans and pre-set permissions in charge of what happens...

Continue Reading
Rokt's 164% Growth Shows Checkout Ads Have Real Muscle

Updated Category News Views 0

Checkout screens have become valuable real estate, and Rokt is planting a flag right in the middle of them. The New York ecommerce technology company landed on Deloitte's 2026 Technology Fast 500 after posting 164% revenue growth from 2022 through 2025. That is a meaningful number, not decorative corporate confetti, especially in a digital-ad market where plenty of...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 102

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading

Top 5 Most Recently Viewed Articles

Apple Inc. Faces Class Action Lawsuit Over Securities Fraud

Updated Category News Views 299

Overview of the Class Action Lawsuit Against Apple Inc. The renowned law firm of Kessler Topaz Meltzer & Check, LLP has announced a significant class action lawsuit filed against Apple Inc. The lawsuit, now underway in the United States District Court for the Northern District of California, is focused on claims of securities fraud that impact investors of Apple...

Continue Reading
Oslo Stock Market Experiences Decline Amidst Mixed Performances

Updated Category News Views 102

Oslo Stock Market Experiences Decline The recent trading session on the Oslo Stock Exchange closed with a notable decline, reflecting a complex mixture of performances across various sectors. Generally, the market is affected by fluctuations in key industries such as Media, Transport, and Diversified Financials. Sector Performance Analysis The Oslo OBX index, a critical...

Continue Reading
Doodle's Tender Offer Results: Lexibook Holds Strong Position

Updated Category News Views 210

Doodle's Tender Offer Results Overview In a strategic move within the shares market, the results from Doodle's recent tender offer on Lexibook have been announced. This development is particularly interesting for investors and stakeholders in the electronic leisure products sector. The outcome signifies a notable consolidation of shares following the initiation of...

Continue Reading
Riot Platforms Sees Bullish Signals as Options Trade Surge

Updated Category News Views 283

Riot Platforms Sees Bullish Signals in Options Trading Recent market activities suggest that investors with significant capital are betting on a positive future for Riot Platforms (NASDAQ: RIOT). This turn towards bullish behavior in the stock market highlights the enthusiasm among wealthier traders and institutional investors. The fascinating aspect of this situation is...

Continue Reading
Highlights from Coloplast A/S Annual Meeting and Future Outlook

Updated Category News Views 215

Coloplast A/S Annual General Meeting Insights Coloplast A/S recently hosted its Annual General Meeting, where significant resolutions were discussed and approved. As the company continues to innovate in healthcare, these decisions reflect their commitment to improving the lives of millions. Annual Report Approval One of the main highlights at the meeting was the approval...

Continue Reading